PMID- 33142189
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1532-2785 (Electronic)
IS  - 0143-4179 (Linking)
VI  - 84
DP  - 2020 Dec
TI  - Increased monocyte chemoattractant protein-1 and nitrotyrosine are associated 
      with increased body weight in patients with rheumatoid arthritis after etanercept 
      therapy.
PG  - 102100
LID - S0143-4179(20)30118-9 [pii]
LID - 10.1016/j.npep.2020.102100 [doi]
AB  - OBJECTIVES: Etanercept, a tumor necrosis factor inhibitor, is an effective drug 
      for patients with active rheumatoid arthritis (RA). Monocyte chemoattractant 
      protein-1 (MCP-1) and nitrotyrosine (NT) are pro-inflammatory biomolecules 
      associated with satiety and increased body weight. We evaluated whether MCP-1 and 
      NT are associated with decreased inflammation or increased body mass during 
      etanercept therapy in active RA patients. METHODS: RA patients with moderate to 
      high disease activity were enrolled to receive add-on etanercept (25 mg 
      subcutaneous injection, biweekly) for at least one year, combined with sustained 
      treatment with conventional synthetic disease-modifying anti-rheumatic drugs 
      (csDMARDs). RESULTS: Forty patients received add-on etanercept and 15 received 
      DMARDs alone. At the end of one year, etanercept significantly reduced the 
      disease activity score of 28 joints, C-reactive protein, and erythrocyte 
      sedimentation rate. Moreover, etanercept significantly increased the body weight, 
      body mass index (BMI), as well as MCP-1 and NT levels, compared to that in the 
      csDMARD-only group. CONCLUSIONS: Increased serum MCP-1 and NT levels in RA 
      patients with moderate to high disease activity, who underwent one-year 
      etanercept treatment, might be attributed to increase in body weight and BMI 
      rather than induction of more severe autoimmune inflammation.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Huang, Hsien-Hao
AU  - Huang HH
AD  - Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei 11217, 
      Taiwan; Institute of Emergency and Critical Medicine, National Yang-Ming 
      University School of Medicine, Taipei 11221, Taiwan.
FAU - Chen, Liang-Yu
AU  - Chen LY
AD  - Aging and Health Research Center, National Yang-Ming University School of 
      Medicine, Taipei 11221, Taiwan; Center for Geriatrics and Gerontology, Taipei 
      Veterans General Hospital, Taipei 11217, Taiwan.
FAU - Chen, Kuan-Yang
AU  - Chen KY
AD  - Division of Digestive Medicine, Taipei City Hospital Ren-Ai Branch, Taipei 10629, 
      Taiwan.
FAU - Lee, Yu-Chi
AU  - Lee YC
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 
      11490, Taiwan.
FAU - Tsai, Chang-Youh
AU  - Tsai CY
AD  - Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei 11217, Taiwan. Electronic address: 
      cytsai@vghtpe.gov.tw.
FAU - Chen, Chih-Yen
AU  - Chen CY
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei 
      Veterans General Hospital, Taipei 11217, Taiwan; Faculty of Medicine, National 
      Yang-Ming University School of Medicine, Taipei 11221, Taiwan; Chinese Taipei 
      Society for the Study of Obesity, Taipei 11031, Taiwan. Electronic address: 
      chency@vghtpe.gov.tw.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Netherlands
TA  - Neuropeptides
JT  - Neuropeptides
JID - 8103156
RN  - 0 (Antirheumatic Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*metabolism
MH  - Chemokine CCL2/blood/metabolism/*therapeutic use
MH  - Etanercept/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Tyrosine/analogs & derivatives/pharmacology
MH  - Weight Gain/physiology
OTO - NOTNLM
OT  - Etanercept
OT  - Monocyte chemoattractant protein-1
OT  - Nitrotyrosine
OT  - Rheumatoid arthritis
EDAT- 2020/11/04 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/11/03 20:13
PHST- 2020/05/22 00:00 [received]
PHST- 2020/10/07 00:00 [revised]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/11/04 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2020/11/03 20:13 [entrez]
AID - S0143-4179(20)30118-9 [pii]
AID - 10.1016/j.npep.2020.102100 [doi]
PST - ppublish
SO  - Neuropeptides. 2020 Dec;84:102100. doi: 10.1016/j.npep.2020.102100. Epub 2020 Oct 
      26.